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Association of Molecular Senescence Markers in Late-Life Depression
With Clinical Characteristics and Treatment Outcome
Breno S. Diniz, MD, PhD; Benoit H. Mulsant, MD; Charles F. Reynolds III, MD; Daniel M. Blumberger, MD; Jordan F. Karp, MD; Meryl A. Butters, PhD;
Ana Paula Mendes-Silva, PhD; Erica L. Vieira, PhD; George Tseng, PhD; Eric J. Lenze, MD

Abstract

Key Points

IMPORTANCE Many older adults with depression do not experience remission with antidepressant
treatment, and markers of cellular senescence in late-life depression (LLD) are associated with
greater severity of depression, greater executive dysfunction, and higher medical illness burden.
Since these clinical characteristics are associated with remission in LLD, molecular and cellular
senescence abnormalities could be a possible biological mechanism underlying poor treatment

Question Are markers associated with
the senescence-associated secretory
phenotype (SASP) associated with
treatment remission in older adults with
major depressive episode?
Findings In this nonrandomized clinical

response in this population.

trial of 416 participants, higher SASP

OBJECTIVE To examine whether the senescence-associated secretory phenotype (SASP) index was

index, a composite score of 22

associated with the likelihood of remission from a depressive episode in older adults.

biomarkers associated with the SASP,
was significantly associated with lower

DESIGN, SETTING, AND PARTICIPANTS A nonrandomized, open-label clinical trial was conducted

likelihood of remission to antidepressant

between August 2009 and August 2014 in Pittsburgh, Pennsylvania; St Louis, Missouri; and Toronto,

treatment.

Ontario, Canada, with older adults in a current major depressive episode according to the Diagnostic
and Statistical Manual of Mental Disorders (Fourth Edition, Text Revision) diagnostic criteria. Data
from biomarker analyses were reported according to the clinical trial archived plasma samples run in
March 2021. Data were analyzed from June to November 2021.

Meaning These findings suggest that
molecular and cellular senescence
abnormalities could be a putative
mechanism associated with worse
treatment outcomes in older adults with

EXPOSURE Venlafaxine extended release (dose ranging from 37.5 mg to 300 mg daily) for up to

a major depressive episode.

12 weeks.
MAIN OUTCOMES AND MEASURES The association between a composite biomarker-based index
(SASP index) and treatment remission in older adults with major depression was measured using
clinical data and blood samples.

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

RESULTS There were 416 participants with a mean (SD) age of 60.02 (7.13) years; 64% (265
participants) were self-reported female, and the mean (SD) Montgomery-Asberg Depression Rating
Scale score was 26.6 (5.7). Higher SASP index scores were independently associated with higher
rates of nonremission, with an increase of 1 unit in the SASP index score increasing the odds of
nonremission by 19% (adjusted odds ratio, 1.19; 95% CI, 1.05-1.35; P = .006). In contrast, no
individual SASP factors were associated with remission in LLD.
CONCLUSIONS AND RELEVANCE Using clinical data and blood samples from a nonrandomized
clinical trial, the results of this study suggest that molecular and cellular senescence, as measured
with the SASP index, is associated with worse treatment outcomes in LLD. Combining this index
score reflecting interrelated biological processes with other molecular, clinical, and neuroimaging
markers may be useful in evaluating antidepressant treatment outcomes. These findings inform a
path forward for geroscience-guided interventions targeting senescence to improve remission rates
in LLD.
(continued)
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Introduction
Achieving response and remission in older adults with major depressive disorder (late-life depression
[LLD]) is a major clinical challenge. Treatment response and remission rates in LLD are approximately
50% after first-line antidepressant treatment.1 Nonremission leads to persistent depressive
symptoms, a source of depleted psychological well-being, increased disability, accelerated cognitive
decline, and premature mortality in older adults.2 Therefore, identifying mechanisms and factors
associated with treatment outcomes is key for improving therapeutics and for a priori identification
of individuals for whom antidepressant treatment would be more effective. A recent meta-analysis3
identified higher baseline depression severity, comorbid anxiety, and executive dysfunction as the
most important clinical variables associated with poor treatment response in LLD. Other studies4-7
have also identified cardiovascular risk factors (eg, metabolic syndrome), cerebrovascular disease,
brain structural changes, physical comorbidity, and frailty as variables associated with poor treatment
response. Some of these variables are common in depression across the lifespan (eg, comorbid
anxiety and depression severity), but others are geriatric specific (eg, cerebrovascular disease
burden and executive dysfunction), suggesting that remission with treatment in LLD may have
specific mechanisms that are associated with age-related brain and systemic aging processes.
From a geroscience perspective, identifying and targeting biological processes associated with
biological aging can ideally prevent, or at a minimum delay, the onset and progression of multiple
chronic diseases and adverse age-related health outcomes that are typically observed in older
adults.8,9 Previous works have suggested the involvement of biological aging and cellular senescence
abnormalities in the biological mechanisms of LLD. For example, abnormalities in proteostasis
control, heightened proinflammatory status, mitochondrial dysfunction, insulin resistance, and
metabolic dysregulation have been described in LLD. They are associated with cognitive impairment,
physical comorbidity burden, and higher mortality risk.10-15 Cellular senescence and changes in its
cellular secretome (ie, the senescence-associated secretory phenotype or SASP) are other important
hallmarks of biological aging.16 The SASP factors comprise several signaling proteins associated with
inflammatory control, tissue remodeling, cell growth, cell cycle control, and metabolic regulation.
They act in concert in different tissues and cell types, propagating prosenescence signals, leading to
cellular senescence changes in neighboring cells and distant tissues.17,18 Reflecting these multiple
interrelated biological pathways and functions, examining them as a biomarker-composite index may
be more robust than examining each individual factor separately for examining disease outcomes,
much as polygenic risk scores are more predictive than a single source of genetic variation.19 For
example, recent studies have shown that a SASP index, including 22 SASP factors, is substantially
elevated in LLD and associated with the severity of depressive symptoms, executive dysfunction, the
burden of physical comorbidity, and markers of worse brain health.20-23
Biological mechanisms of aging itself may drive LLD treatment outcomes. A genome-wide
association study,24 including 184 individuals treated with venlafaxine extended release (XR), has
identified 8 loci associated with treatment remission in LLD. The most common biological pathways
associated with these genes were proteostasis regulation (eg, ubiquitin-proteasome system) and
vascular health. Another recent study,25 including 64 older adults with LLD, investigated the
transcriptomic profile associated with remission with escitalopram and memantine treatment and
showed that both medications strongly modulated inflammatory responses. Other biological
pathways associated with remission were cellular proliferation, apoptosis (escitalopram only),
cellular clearance, metabolism, and cytoskeletal dynamics (escitalopram and memantine). These
studies point to processes implicated in accelerated biological aging (ie, immunoinflammatory
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response, cellular proliferation and apoptosis, and metabolic control) as mechanisms and variables
associated with treatment response and remission in LLD.16
Thus, we undertook an analysis to evaluate whether SASP factors, systemic indicators of
abnormal cellular senescence, were associated with treatment remission in a large sample of older
adults with LLD. Our primary hypothesis was that a higher composite score of SASP factors (the SASP
index) would be associated with treatment resistance (ie, nonremission to venlafaxine XR
treatment). We also evaluated the association between the SASP index and demographic and clinical
characteristics.

Methods
In this nonrandomized controlled trial, we analyzed blood samples and clinical data from participants
in the open-label phase of the Incomplete Response in Late-Life Depression: Getting to Remission
(IRLGREY) Study, a 3-site trial in which treatment remission was assessed prospectively.26 This study
reports secondary data analyses focusing on the association between blood-based biomarkers and
treatment remission according to data available from the IRLGREY study. The prespecified primary
and secondary outcomes have been previously published.26,27 Participants provided written
informed consent, and ethics approval was obtained from the institutional review boards at the
Centre for Addiction and Mental Health in Toronto, the University of Pittsburgh, and Washington
University in St Louis. This study follows the Transparent Reporting of Evaluations With
Nonrandomized Designs (TREND) reporting guideline. The trial protocol is available in Supplement 1.

Study Sample
The IRLGREY study, conducted between August 2009 and August 2014, has been described in detail
previously.26 Participants were aged 60 years or older and had current nonpsychotic major
depressive disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders
(Fourth Edition, Text Revision) (DSM-IV-TR) diagnostic criteria28 with a score of 15 or higher on the
Montgomery-Asberg Depression Rating Scale (MADRS).29 The diagnosis of MDD and the presence of
a major depressive episode were confirmed with the Structured Clinical Interview for DSM-IV-TR Axis
I Disorders (SCID-IV-TR), Research Version, Patient Edition.30 Exclusions were lifetime diagnosis of
bipolar disorder, schizophrenia, schizoaffective disorder, other psychotic disorders, or current
psychotic symptoms; clinical history of dementia; alcohol or substance use disorder in the past 6
months; imminent suicide risk; unstable physical illness; or contraindication to venlafaxine XR.

Intervention
Participants were treated for up to 12 weeks openly with venlafaxine XR. Participants started at 37.5
mg per day and flexibly titrated as needed up to 300 mg per day following a standardized protocol
as published previously.26

Outcome Measure and Additional Demographic and Clinical Variables
Depression symptom severity was measured by the MADRS score assessed at study baseline, week
1, week 2, and every 2 weeks thereafter for 12 weeks, with remission defined as MADRS scores of 10
or below for 2 consecutive assessments at phase end.
Demographic (age, self-reported sex, self-reported race [Black, White], years of education) and
anthropometric (weight, height) data were obtained in the baseline assessment. Race was assessed
in this study because it is a social variable that can influence access to treatment and the
antidepressant remission rates. Body mass index (BMI) was calculated as weight in kilograms divided
by height in meters squared. Blood pressure was measured while sitting after at least 5 minutes of
resting. Systolic and diastolic blood pressure values are the mean of 2 measurements taken 5 minutes
apart. Physical comorbidity burden was assessed with the Cumulative Illness Rating
Scale–Geriatrics.31
JAMA Network Open. 2022;5(6):e2219678. doi:10.1001/jamanetworkopen.2022.19678 (Reprinted)
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Information about the participant’s history, including the length of the current depressive
episode, age of onset of the first depressive episode, depressive episode recurrence, and presence
of comorbid anxiety disorder, was obtained during the SCID-IV-TR interview. In addition, the MDD
was classified as early-onset depression (EOD) or late-onset depression (LOD) depending on whether
the first depressive episode happened before or after the age of 60 years.
A neuropsychological test battery was administered before starting venlafaxine XR. Executive
function was evaluated using 2 tests from the Delis-Kaplan Executive Function System—the ColorWord Interference task (measuring response inhibition) and the Trail Making Test (measuring
set-shifting and cognitive flexibility).32 The Color-Word Interference condition 3, called inhibition,
assesses the ability to inhibit an automatic response (ie, reading words); instead, participants must
produce a response that requires more effort (ie, naming the colors of words). The Trail Making Test
condition 4 (also known as the Number-Letter Switching condition) requires participants to switch
back and forth between connecting numbers and letters (ie, 1-A, 2-B, to 16-P). Condition 5 is a motor
speed condition in which participants trace over a dotted line connecting circles on the page as
quickly as possible to gauge their motor drawing speed. Comparing performance on condition 4
(which assesses cognitive flexibility) with performance on condition 5 (which assesses motor speed)
removes the motor speed element from the test score to ascertain cognitive flexibility33; thus, to
evaluate set-shifting performance, we used the Delis-Kaplan Executive Function System normed
scaled score (with a mean [SD] score of 10 [3]) for the difference in speeds between condition 4 and
condition 5.34 All tests were scored according to published age-adjusted norms for each test,28-30
and additional details about the neuropsychological testing and scoring can be found elsewhere.27

SASP Factors
Blood was collected by venipuncture with EDTA tubes after overnight fasting and processed
immediately after collection. Plasma was obtained from the blood by centrifugation at 3000 g for 10
minutes at 4 °C. Plasma was separated, aliquoted, and stored in a −80 °C freezer until the laboratory
analysis.
The SASP factors were analyzed by a customized multiplex assay (R&D System) using the
Luminex 100/200 platform (Luminex). All the experiments were performed according to the
manufacturer's instructions. All the biomarkers were analyzed using the same assay batch, and the
coefficient of variation was less than 10% for all analytes. All samples were analyzed on the same day
to reduce variability across laboratory experiments.
The SASP factors included in the SASP index are the IGFBP6, IGFBP2, CCL4, interleukin-1β,
granulocyte-macrophage-colony-stimulating factor, placental growth factor, angiogenin, migration
inhibitory factor–1, macrophage inflammatory protein (MIP)–1α, chemokine growth-regulated protein
α, interleukin-6, human monocyte chemoattractant protein–4, glycoprotein 130, intercellular
adhesion molecule–1, monocyte chemoattractant protein-1, interleukin-8, MIP-3α, osteoprotegerin,
metallopeptidase inhibitor–1, urokinase-type plasminogen activator receptor, tumor necrosis factor
(TNF) receptor–I, and TNF receptor–II. We selected the candidate SASP proteins included in our
analyses according to previous preclinical studies focused on the changes in the secretome pattern
of senescent cells35 and our previous publications.20,22 The raw data were log2 transformed and
standardized to the z score. We calculated the SASP index score for each participant according to the
following regression formula: SASP index = β1x1 + … + β22x22, where β is the individual weight and x
is the standardized value of each biomarker included in the SASP index. The weight for each factor
was derived from a previous publication20 from our group using an independent and clinically
heterogeneous sample of older adults with and without a history of MDD (eTable 1 in Supplement 2).
The SASP index mean was centered at 0, with an SD of 1 in the whole sample.

Statistical Analysis
First, we conducted a descriptive analysis of all the continuous variables and the visual inspection of
P-P plots to evaluate whether they followed a normal distribution. The variables that did not show
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a normal distribution were log-transformed. Then, we performed 2-sided t tests to assess the
association between demographic variables (eg, sex) or characteristics of the MDD (eg, LOD vs EOD)
and the SASP index scores. We also performed Pearson correlation analyses to evaluate the
association between SASP index scores, baseline demographics, clinical data, and executive function
performance data.
We evaluated whether treatment outcome (nonremission vs remission) was associated with
differences in SASP index score or other baseline demographic, clinical, and executive function
performance data using t tests. Analyses of covariance were done to evaluate the relevance of
potential covariates on the association between treatment outcome and the SASP index score.
Finally, we performed a logistic regression analysis to assess potential variables associated with
treatment outcome to venlafaxine XR (treatment resistance as the reference group). First, we
evaluated whether the SASP index scores baseline demographic, clinical, and executive function
performance data were associated with treatment resistance in unadjusted models (a total of 12
analyses were run in the unadjusted logistic regression analyses). Then, variables that were
significantly associated with treatment resistance in the unadjusted model (ie, variables with P < .05)
were entered simultaneously in the model (adjusted model). We did not test the interaction between
the SASP index and covariates in the logistic regression models. We used the Hosmer-Lemeshow
test to evaluate the goodness-of-fit of the model. We also did the same set of analyses with each
SASP factor. All analyses were performed using Stata statistical software version 17 for Windows
(StataCorp). Data were analyzed from June to November 2021.

Results
SASP Index and Baseline Characteristics
Participants totaled 416 and were included in this analysis if they had complete data from baseline
and at least 1 follow-up visit, plus baseline biomarker data. Participants’ mean (SD) age was 60.0 (7.1)
years, 64% (265 participants) were self-reported female, and the mean (SD) MADRS score was 26.6
(5.7). Table 1 shows the demographic and clinical characteristics of the sample, broken down by their
remission status.
The 103 participants with LOD had significantly higher SASP index scores than the 313
participants with EOD (mean [SD], 0.39 [0.16] vs −0.05 [0.10]; t414 = 2.25; P = .02). Self-reported
male sex was significantly associated with higher SASP index scores (mean [SD], 0.41 [0.12] for male
vs −0.13 [0.11] for female; t414 = 3.16; P = .002). (Figure 1). In the full sample, higher SASP index
scores were associated with older age (r = 0.22; P < .001), higher physical comorbidity burden
(r = 0.37; P < .001), higher BMI (r = 0.23; P < .001), higher systolic blood pressure (r = 0.11; P = .02),
and worse performance on executive function tests (set shifting score r = −0.16; P = .001; inhibition
score, r = −0.19; P < .001; inhibition-switching score, r = −0.19; P < .001) (Figure 2). The SASP index
scores were not significantly associated with MADRS scores (r = −0.03; P = .53), duration of the
current depressive episode (r = 0.07; P = .14), educational level (r = −0.09; P = .07), or diastolic
blood pressure measures (r = −0.02; P = .60).

SASP Index and Treatment Outcomes With Venlafaxine XR
With open-label treatment with venlafaxine XR, 176 participants achieved remission (remission
group) and 240 did not (nonremission group). Participants in the nonremission group were more
frequently male, had higher pretreatment MADRS scores, longer current depressive episode, higher
diastolic blood pressure, and higher SASP index scores than those in the remission group (Table 1).
The association between the SASP index scores and nonremission remained significant (F5,407 = 5.37;
P = .02) after controlling for the effect of sex (F5,407 = 8.36; P = .004), baseline depressive
symptoms (F5,407 = 0.05; P = .80), length of the current depressive episode (F5,407 = 1.09; P = .29),
and diastolic blood pressure levels (F5,407 = 1.73; P = .19). (Figure 1). Since sex and age of onset were
associated with SASP index, we also tested whether they were moderators of the association
JAMA Network Open. 2022;5(6):e2219678. doi:10.1001/jamanetworkopen.2022.19678 (Reprinted)
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between treatment outcome and SASP index. Neither sex (F3,412 = 2.81; P = .09) nor age of onset of
MDD (F3,412 = 0.04; P = .84) significantly moderated the association between treatment outcomes
and the SASP index.
Since the SASP index includes 22 independent biomarkers, we also explored the association
between each biomarker and remission status. We found that the MIP-3α and TNFRII were
significantly higher in those with nonremission (eTable 1 in Supplement 2). However, this association
did not remain significant after controlling for the covariates (sex, severity of baseline depressive
symptoms, length of current depressive episode, and diastolic blood pressure) (eTable 1 in
Supplement 2).
In the logistic regression analysis, a higher SASP index score was associated with a higher risk of
nonremission, with an increase of 1 unit of the SASP index scores, increasing the risk of nonremission
by 16% (odds ratio [OR], 1.16; 95% CI, 1.06-1.30; Wald = 6.47; P = .01). In the adjusted model,
including sex, MADRS scores, and cognitive inhibition and set-shifting scores, the SASP index scores
remained independently associated with a 19% higher risk of nonremission of the major depressive
episode (OR, 1.19; 95% CI, 1.05-1.35l; Wald = 7.48; P = .006) (Table 2). We also evaluated the
association between each 22 independent SASP biomarkers and treatment outcomes. Again, the
only biomarker that was associated with nonremission was the MIP-3α (OR, 1.11; 95% CI, 1.00-1.23;
Wald = 4.08; P = .045). However, this association did not remain significant in the adjusted model
(OR, 1.09; 95% CI, 0.98-1.22; Wald = 2.46; P = .12) (eTable 2 in Supplement 2).

Table 1. Sample Characteristics According to Treatment Outcome After Treatment With Venlafaxine
Extended Release
Patients, No. (%), by treatment
outcome
Nonremission
(n = 240)

Remission
(n = 176)

Female

139 (58)

126 (72)

Male

101 (42)

50 (28)

Characteristic

Statistics

P value

χ 21 = 7.74

.005

Self-reported sex

Age, mean (SD), y

68.6 (6.9)

69.7 (7.4)

t414 = 1.54

.12

Education, mean (SD), y

14.2 (2.8)

14.7 (2.8)

t414 = 1.65

.10

Black

29 (12)

17 (10)

White

211 (88)

159 (90)

χ 21 = 0.35

.55

Montgomery-Asberg Depression Rating Scale
score, mean (SD)

27.7 (5.7)

25.1 (5.4)

t414 = 4.72

<.001

Duration of current major depressive episode,
mean (SD), d

342 (673)

215 (508.8)

t414 = 2.10

.04

No

139 (58)

104 (59)

Yes

101 (42)

72 (41)

χ 21 = 0.24

.87

χ 21 = 2.91

.09

Self-reported race

Comorbid anxiety diagnosis

Age of onset of major depressive disorder
Late onset depression

68 (28)

51 (29)

Early onset depression

172 (72)

126 (71)

CIRS-G, Cumulative Illness Rating Scale-–
Geriatric total score, mean (SD)

10.1 (4.6)

9.6 (4.2)

t414 = 1.18

.23

Body mass index, mean (SD)a

29.8 (7.3)

29.6 (6.0)

t414 = 0.25

.73

Systolic

133.4 (19.4)

130.3 (18.7)

t414 = 0.92

.10

Diastolic

77.5 (11.6)

74.7 (11.5)

t414 = 2.40

.02

Set shifting score, mean (SD)

8.5 (4.1)

8.9 (4.1)

t414 = 0.93

.35

Response inhibition score, mean (SD)

10.4 (3.1)

10.2 (2.9)

t414 = 0.65

.52

Response inhibition-shifting score,
mean (SD)

9.9 (3.4)

10.2 (3.7)

t414 = 1.01

.31

Senescence-associated secretory phenotype
index score, mean (SD)

0.25 (0.10)

−0.19 (0.14)

t414 = 2.58

.01

Blood pressure, mean (SD), mm Hg

JAMA Network Open. 2022;5(6):e2219678. doi:10.1001/jamanetworkopen.2022.19678 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User on 11/16/2022

a

Body mass index is calculated as weight in kilograms
divided by height in meters squared.
June 30, 2022

6/14

JAMA Network Open | Psychiatry

Association of Molecular Senescence Markers in Late-Life Depression With Treatment Outcome

Discussion
In this nonrandomized controlled trial, we explored whether circulating molecular markers of cellular
senescence (SASP factors) were prospectively associated with nonremission to venlafaxine
treatment in a large sample of older adults with MDD. A higher SASP index composite score was a
significant and independent variable associated with nonremission in this population. By contrast,
none of the individual SASP biomarkers was independently associated with remission status. We also
showed that higher SASP index scores were associated with specific characteristics of the depressive
episode as a geriatric syndrome, namely, later age of onset, a higher burden of medical comorbidity,
and executive dysfunction. This is important because it demonstrates that the key interrelated
biological processes of aging called senescence may underlie many cases of LLD, particularly in the
context of poor treatment response. This finding is concordant with research on late-life
neuropsychiatric disorders and could lead to geriatric-specific solutions to improve treatment
outcomes in mental disorders by interrogating and intervening at the level of cellular aging.36,37
Inflammatory markers constitute a significant component of the SASP index,38 and several
studies have addressed whether inflammatory markers are associated with antidepressant
treatment outcomes, with mixed results. For example, in an early study of younger adults with MDD
treated with escitalopram for 12 weeks, higher serum TNF-α was associated with a worse treatment
response.39 However, in 2 other studies, plasma levels of TNF-α, TNF-α receptors, or other
inflammatory biomarkers (eg, C-reactive protein, interleukin-6) did not project response or remission
to treatment with sertraline, transcranial direct current stimulation, or omega-3 fatty acid.40,41 In a
study of 52 young participants with MDD treated with venlafaxine, none of 7 inflammatory markers
were individually associated with treatment response.42 However, recent meta-analyses43,44
suggested that higher levels of interleukin-8 and C-reactive protein are associated with worse
treatment response in MDD, although these associations had small effect sizes. All these studies
evaluated whether individual biomarkers were associated with outcome; none assessed whether a
composite index was associated with antidepressant treatment outcome, and they focused mostly
on a young and middle-aged adult population.
Like these other studies, none of our individual inflammatory (or other) biomarkers was
associated with remission with antidepressant treatment. By contrast, when all these biomarkers
were incorporated into a single composite index (SASP index) associated with different pathways
affected by pathological aging processes (eg, inflammation, metabolic control, cell growth, and
tissue remodeling), the SASP index showed a robust association with remission in LLD. Our findings,

Figure 1. Senescence-Associated Secretory Phenotype (SASP) Index Scores According to Treatment Response, Age of Onset of the Depressive Disorder, and Sex
A

B

Treatment response
0.50

P =.01

C

Age of onset
0.75

P =.03

Sex
P =.002

0.75

0.50

0

–0.25

SASP index score

0.50

SASP index score

SASP index score

0.25

0.25

0.25

0

0
–0.25

–0.50

–0.25
Treatment
resistance

Remission

Treatment outcome

–0.50
LOD

EOD

Age of onset

Women

Men

Sex

Dots indicate mean and whiskers indicate 95% CI. EOD indicates early-onset depression; LOD, late-onset depression.
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thus, provide evidence that moving beyond the 1 disease, 1 molecule paradigm by incorporating
multiple biomarkers reflecting different biological pathways into a composite index can be more
powerful in informing the biological mechanisms associated with treatment outcomes for psychiatric
disorders. Other examples in psychiatry include the development of polygenic risk scores to
investigate the mechanisms and biological variables associated with treatment response in major
depression.45-47
Previous works have explored the association between telomere length, a robust marker of
cellular senescence, and MDD across the lifespan. Overall, there is evidence of shorter leukocyte
telomere length in patients with MDD, with mild to moderate effect size (Cohen d = −0.205).48 Also,
a recent study49 reported a substantial association between the severity of the depressive episode
in LLD and shorter leukocyte telomere length. A few small clinical trials50-52 evaluated whether
leukocyte telomere length was associated with treatment response or remission in MDD, with mixed
results. None of these studies included older adults with LLD, a population more vulnerable to
age-related biological abnormalities.53 Our previous study18 evaluated the association of molecular
and cellular senescence with the outcome of protocolized antidepressant treatment in a large sample
of older patients with MDD. We focused on well-established circulating SASP factors.15-17 Our finding
that a higher SASP index score, reflecting more intense molecular and cellular senescence
abnormalities, is associated with treatment outcome supports the hypothesis that enhanced

Figure 2. Scatterplots of the Association Between Senescence-Associated Secretory Phenotype (SASP) Index Scores, Age, Medical Comorbidity Burden and Executive
Function Performance
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Dots indicate each individual included in the analysis; shaded area indicates 95% CI for the linear trend; line indicates linear trend. CIRS-G indicates Cumulative Illness Rating Scale–
Geriatrics.
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age-related biological changes render older individuals with LLD less prone to achieve remission of
the depressive episode.
These previous results and our congruent findings suggest that molecular and cellular
senescence abnormalities may be a common mechanism negatively associated with treatment
outcomes indirectly and directly. Cellular senescence and the SASP are viewed as responses to
different stressors that lead to cell dysfunction (eg, DNA damage and loss of proteostasis).54,55 The
accumulation of senescent cells leads to a gradual loss of the capacity of tissues to optimally
compensate homeostatic function against deleterious stimuli and recover normal function even after
removing the noxious stimuli.56,57 The accumulation of senescent cells in different tissues and SASP
factors systemically can lead to the incidence of various age-related diseases and worse medical
outcomes.17,58 In the context of our study, we can speculate that a higher SASP index is a general
indicator of systemic and brain dysfunction that leads to a worse response to antidepressants.
Moreover, these poor outcomes observed in LLD can also reflect a broader process of unhealthy
aging that can be identified by an elevated SASP index. Interventions and lifestyle modifications,
including increased physical activity, improved dietary patterns, and good management of chronic
medical conditions, contribute to improved general health, possibly by regulating different
age-related biological processes and slowing of molecular and cellular senescence.59-61 Importantly,
these lifestyle and behavioral factors are protective against the development of depressive
symptoms and can be used as adjunctive treatment options to improve treatment response in older
adults with major depression,62-64 but also can be useful for the prevention of other age-related
outcomes commonly observed in this population. Finally, geroscience-guided interventions, such as
using senolytic drugs that specifically clear senescence cells aiming to reduce or mitigate cellular
senescence and the harmful effects of SASP factors,65 could be used to improve antidepressant
treatment outcomes in LLD. Such strategies have recently showed promising results to mitigate
anxiety and cognitive impairment after chronic stress in different animal models.37,66

Table 2. Logistic Regression to Determine Factors Associated With Treatment Outcome
Adjusteda

Unadjusted
Variable

OR (95% CI)

Wald

P value

OR (95% CI)

Wald

P value

Senescence-associated secretory phenotype
index score

1.16 (1.06-1.30)

6.47

.01

1.19 (1.05-1.35)

7.48

.005

Self-reported sex

2.060 (1.26-3.37)

8.243

.004

1.86 (1.23-3.11)

8.00

.005

MADRS score

0.908 (0.87-0.95)

19.99

<.001

1.10 (1.06-1.14)

23.48

<.001

Duration of MDE

1.000 (0.99-1.00)

3.557

.06

NA

NA

NA

Age

1.007 (0.97-1.04)

.141

.71

NA

NA

NA

Self-reported race

1.099 (0.51-2.37)

.058

.81

NA

NA

NA

Years of education

1.077 (0.99-1.17)

2.915

.09

NA

NA

NA

CIRS-G

.956 (0.90-1.01)

2.501

.11

NA

NA

NA

Set shifting

1.117 (1.00-1.24)

4.246

.04

1.06 (1.00-1.13)

3.87

.05

Response inhibition

.867 (0.78-0.96)

7.702

.006

1.10 (1.01-1.19)

5.21

.02

Response inhibition-shifting

1.077 (0.99-1.18)

2.741

.01

NA

NA

NA

Comorbid anxiety diagnosis

.941 (0.59-1.49)

.066

.79

NA

NA

NA

Systolic

1.000 (0.99-1.01)

.001

.98

NA

NA

NA

Diastolic

.983 (0.96-1.01)

1.763

.18

NA

NA

NA

1.014 (0.98-1.05)

.562

.453

NA

NA

NA

Blood pressure

BMIb

Abbreviations: BMI, body mass index; CIRS-G, Cumulative Illness Rating Scale-Geriatric;
MADRS, Montgomery-Asberg Depression Rating Scale; MDE, current major depressive
episode; NA, not applicable; OR, odds ratio.
a

b

Body mass index is calculated as weight in kilograms divided by height in
meters squared.

Adjusted by self-reported male sex, MADRS scores, and scores on cognitive inhibition
and set-shifting tasks. OR greater than 1.0 indicates a higher risk of
nonremission status.
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Several variables were significantly associated with a higher SASP index among the LLD
participants. Self-reported sex was associated with the SASP index scores, with male participants
having higher SASP index scores than female participants. A meta-analysis showed that biological sex
was not significantly associated with leukocyte telomere length and MDD.67 Our study offers
additional evidence that biological sex can be significantly associated with biological hallmarks of
aging in LLD, with male individuals showing a higher SASP index score. This finding could explain the
higher risk of poorer outcomes, such as higher mortality, in older male individuals with MDD
compared with female individuals.68 Several lines of evidence suggest that patients with late-onset
depression and early-onset depression have distinct biological mechanisms69 and long-term,
age-related outcomes (eg, more rapid cognitive decline in LOD vs EOD).70 In our study, participants
with LOD had higher SASP than EOD, again providing additional evidence for potential distinct
mechanisms between these 2 subgroups of LLD.

Strengths and Limitations
Our study has some strengths (eg, a large sample and the use of protocolized antidepressant
treatment to prospectively characterize outcome) and limitations. First and foremost, all participants
were treated with venlafaxine XR, and we cannot distinguish whether the association between
higher SASP index scores and nonremission is specific to venlafaxine or reflects a more general effect
of molecular and cellular senescence on treatment remission in LLD. We did not have a specific
measure of vascular risk scores in this sample, but a more systemic measure of medical burden (the
Cumulative Illness Rating Scale–Geriatrics), and we may not have more detailed information about
the association between the SASP index and vascular risk factors. Also, our sample mainly included
White participants, and our results may not be generalizable to other racial or ethnic groups. Another
potential limitation was the inclusion of participants who have a history of alcohol use disorder as
long as it was in remission for at least 6 months. This duration may not be sufficient to rule out the
impact of alcohol use disorder on senescence markers. However, we have previously reported on the
absence of association between previous or current alcohol use and SASP index.21 Thus, it is unlikely
that the inclusion of participants with a history of alcohol use disorder influenced the current results.

Conclusions
In conclusion, our findings suggest that molecular and cellular senescence, as measured with the
SASP index, is significantly associated with worse treatment outcomes in LLD. Our study also
demonstrates that a composite index, integrating biomarkers reflecting distinct but interrelated
biological processes, is superior to any single biomarkers in the association with treatment remission
in LLD. Our findings can inform a path forward for geroscience-guided interventions targeting
senescence to improve remission rates in LLD.
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